AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
=== Linear copolymers === Due to the wide variety of copolymers possible, there is no single accepted naming convention, but IUPAC has a general suggested naming scheme that indicates the organization of repeat units within a copolymers. In this convention, source based nomenclature is used to indicate the monomers from which the copolymer was synthesized. Following the IUPAC naming conventions, a generally copolymer is named poly(A-co-B), where A and B are the monomers and -co- represents the type of copolymer. This linkers changes with the type of copolymers, examples of which are shown below. If the exact structure of the polymer is unknown, the linker -co- should be used.
== Further reading == Bishop, Michael; Duben-Engelkirk, Janet L., and Fody, Edward P. (1992). "Chapter 19, Liver Function, Clinical Chemistry Principles, Procedures, Correlations, 2nd Ed." Philadelphia, J.B. Lippincott Company. Miyabara, Yuichi; Tabata, Masako; Suzuki, Junzo; Suzuki, Shizuo (1992). "Separation and sensitive determination of i-urobilin and 1-stercobilin by high-performance liquid chromatography with fluorimetric detection". Journal of Chromatography B: Biomedical Sciences and Applications. 574 (2): 261–265. doi:10.1016/0378-4347(92)80038-R. PMID 1618958. Miyabara, Y.; Sakata, Y.; Suzuki, J.; Suzuki, S. (1994). "Estimation of faecal pollution based on the amounts of urobilins in urban rivers". Environmental Pollution. 84 (2): 117–122. doi:10.1016/0269-7491(94)90093-0. PMID 15091706. Munson-Ringsrud, Karen and Jorgenson-Linné, Jean (1995). "Urinalysis and Body Fluids, a ColorText and Atlas." St. Louis, Mosby. Nelson, L.; David, Cox M.M. (2005). “Chapter 22 – Biosynthesis of Amino Acids, Nucleotides, and Related Molecules”, pp. 856, In Lehninger Principles of Biochemistry. Freeman, New York. pp. 856. Voet, Donald; Voet, Judith G.; Pratt, Charlotte W. (2018-01-23). Voet's Principles of Biochemistry, Global Edition, 5th Edition. Wiley. p. 1200. ISBN 978-1-119-45166-2. Retrieved 2024-02-01.
== College career == In his junior year at Iowa State he made 26 receptions for 330 yards and six touchdowns. However his senior year was marked with numerous injuries. He only recorded six catches and 47 yards over eight games. He suffered from a rare form of muscle cramping causing raised creatine phosphokinase levels which dampened his chances in the 2014 NFL draft. Overall, he recorded 32 catches for 377 yards and 6 touchdowns.
Under the Treaty on the Functioning of the European Union article 56 there is the right to receive services, with rules codified into the Patients' Rights Directive 2011. Article 4 requires that people are treated, article 5 requires reimbursement of costs by the person's country of origin, article 6 requires national contact points to connect healthcare providers or insurers and patient organisations, but under article 8 member states may require prior authorisation for people to travel abroad for treatment where the costs are high or planning is needed. A European Health Insurance Card is also available for free to receive health across the EU. This system was developed after R (Watts) v Bedford Primary Care Trust, where in 2003 Mrs Watts travelled from the UK to France, paid £3900 for a hip replacement operation, and claimed she should be reimbursed. The UK's National Health Service waiting lists were 4 to 6 months at the time. The Court of Justice's Grand Chamber held that health care counted as a 'service' under TFEU article 56, and that in principle there was a right to receive those services abroad. However, high demand could justify waiting lists in a national health system, but individual circumstances of the patient had to be assessed. For non-EU nationals, the European Court of Human Rights held in N v United Kingdom that it was not inhuman and degrading treatment contrary to ECHR article 3 to deport someone to a country where there were unlikely to live longer than two years without treatment.
In periodontology, gingival grafting, also called gum grafting or periodontal plastic surgery, is a generic term for the performance of any of a number of surgical procedures in which the gingiva (gum tissue) is grafted. The aim may be to cover exposed root surfaces or merely to augment the band of keratinized tissue.
Sources: en.wikipedia.org
== Diagnosis == There are various tools that can be used to help diagnose myositis. The most common methods are physical examination, electromyography (EMG), magnetic resonance imaging (MRI), muscle biopsy, and blood tests. The first course of action a doctor will likely take is perform a physical exam. The doctor assesses for muscle weakness or rashes. Another possible test is electromyography. This test involves the insertion of small needles into the patient's muscles. This allows a physician to look at the muscles' responses to various electrical nerve stimuli and evaluate which muscles potentially have myositis. Magnetic resonance imaging can be useful in diagnosis, allowing painless, non-invasive visualisation of any muscle wastage. Muscle biopsies, however, are the most reliable tests for diagnosing myositis. There are also a variety of blood tests available that help in the diagnosis of myositis. The doctor may look for an elevation of creatine kinase in the blood, which is indicative of muscle inflammation. Certain autoantibodies (antibodies that target muscle cells) can also be found in the blood, which can indicate that myositis is caused by an autoimmune disease. Some specific examples of autoantibodies are Anti-Jo-1, Anti-HMGCR, Anti-TIF1, etc.
Natural holmium (67Ho) contains one observationally stable isotope, 165Ho. The known isotopes of holmium range from 140Ho to 175Ho. The primary decay mode before the stable 165Ho, is beta plus decay to dysprosium isotopes, and the primary mode after is beta minus decay to erbium isotopes. Among the synthetic radioactive isotopes the most stable is 163Ho with a half-life of 4,570 years, the next most stable is 166Ho having a half-life of 26.812 hours, and others are under 4 hours. The isomeric nuclide 166m1Ho, however, has a half-life of 1,133 years, much the longest of the meta states. Holmium-166 (ground state) has been studied for medical application.
=== Traditional medicine === Xanthoria parietina has a long history of use in traditional medicine across several cultures. In Andalucia, Spain, this lichen was known as flor de piedra ('stone flower') or rompepiedra ('stone breaker'). Spanish traditional healers employed it for several purposes: treating menstrual complaints when prepared as a decoction in wine, addressing kidney disorders and toothaches when made into water-based decoctions, and serving as a general analgesic. They also incorporated it into cough syrups along with various plant ingredients. In European traditional medicine during the early modern era, X. parietina was boiled with milk to treat jaundice, often alongside Polycauliona candelaria. This application exemplifies the Doctrine of signatures – a belief system that plants resembling parts of the body could treat ailments of those parts – as the yellow-orange color of the lichen was thought to indicate its efficacy against the yellowing of the skin in jaundice. In Traditional Chinese medicine, it was known as Chinese: shí huáng yī ('stone yellow clothes') and valued for its antibacterial properties. The widespread medicinal use of lichens, including X. parietina, had been mostly abandoned by 1800, and these applications represent historical folk remedies rather than evidence-based treatments.
Moreover, engineered knottins have shown significant promise as therapeutics, imaging agents, and targeting agents for chemotherapy. The mammalian proteins Agouti signalling peptide and Agouti related peptide are the only known mammalian examples of this motif. Both are neuropeptides involved in cell signalling. The former is responsible for hair (fur) colouration. The motif is similar to the cyclic cystine knot or cyclotide, but lacks the cyclisation of the polypeptide backbone which is present in the latter family. The growth factor cystine knot (GFCK) is similar to the ICK but its topology is such that it is the bond between the first and fourth disulfide which threads through the loop.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.